340 completed, 84 terminated, 81 recruiting, 80 unknown. 139 Phase 2, 122 Not applicable, 113 Phase 3, 84 Phase 1, 63 Phase 4.
Follow Pulmonary Arterial Hypertension: new trials by email Literature Review of Pulmonary Arterial Hypertension trials Research Report on Pulmonary Arterial Hypertension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets MN-08 24 mg/day, MN-08 60 mg/day - Pulmonary Arterial Hypertension | Phase 1 | Not yet recruiting | Guangzhou Magpie Pharmaceuticals Co., Ltd. | 16 | 2027-09-01 | 2026-09-14 |
| What is the Role of the Exposome in Pulmonary Hypertension Questionnaires, Samples - Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Not yet recruiting | Poitiers University Hospital | 150 | 2027-01-01 | 2026-07-22 | |
| Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension Questionnaire Assessment - Pulmonary Arterial Hypertension (PAH), Quality of Life | Not yet recruiting | Chinese Pulmonary Vascular Disease Research Group | 300 | 2026-12-01 | 2026-10-27 | |
| A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea Pulmonary Arterial Hypertension | Not yet recruiting | Janssen Korea, Ltd., Korea | 333 | 2026-11-02 | 2026-11-03 | |
| Home-based Inspiratory Muscle Training in Pulmonary Hypertension Inspiratory muscle training, Sham inspiratory muscle training - Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension | Not applicable | Not yet recruiting | Universidad Complutense de Madrid | 40 | 2026-11-01 | 2026-11-04 |
| Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO) Discontinuation of parenteral prostacyclins analogues or selexipag - Pulmonary Arterial Hypertension | Not applicable | Not yet recruiting | University of Alberta | 78 | 2026-10-30 | 2026-09-23 |
| The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension Dextrose, Sildenafil 20mg - Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Phase 2 / Phase 3 | Recruiting | Silvia Ulrich | 20 | 2026-10-26 | 2026-11-04 |
| Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) IKT-001 - Pulmonary Arterial Hypertension (PAH) | Phase 3 | Not yet recruiting | Inhibikase Therapeutics | 484 | 2026-10-23 | 2026-06-08 |
| A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) Sotatercept, Background PAH Therapy - Pulmonary Arterial Hypertension | Phase 4 | Recruiting | Merck Sharp & Dohme LLC | 30 | 2026-10-08 | 2026-11-04 |
| Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD) 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX) - Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Not applicable | Recruiting | Silvia Ulrich Somaini | 40 | 2026-10-01 | 2026-09-09 |
| PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension Standardized Overnight Sleep and Cardiorespiratory Monitoring - Pulmonary Arterial Hypertension (PAH), Sleep-disordered Breathing (SDB) | Recruiting | Chinese Pulmonary Vascular Disease Research Group | 1500 | 2026-10-01 | 2026-10-01 | |
| Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung Diseases 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX) - Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Not applicable | Recruiting | Silvia Ulrich Somaini | 40 | 2026-10-01 | 2026-09-09 |
| Myocardial Metabolic Flux in Pulmonary Arterial Hypertension GLP-1 agonist - Pulmonary Arterial Hypertension | Phase 2 | Not yet recruiting | Imperial College London | 32 | 2026-10-01 | 2026-07-30 |
| Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Substudy Measurement of oxyhemoglobin and deoxyhemoglobin concentration pre and post- exercise at baseline and Week 12. Measurement of time to recovery of oxyhemglobin post-exercise at baseline and at Week 12., Blood draw - Pulmonary Arterial Hypertension | Not applicable | Not yet recruiting | University of Pennsylvania | 20 | 2026-09-30 | 2026-08-27 |
| Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) NS-863 Low Dose, NS-863 High Dose, NS-863 Placebo - Pulmonary Arterial Hypertension | Phase 2 | Recruiting | NS Pharma, Inc. | 135 | 2026-09-29 | 2026-10-28 |
| Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Patients With Pulmonary Arterial Hypertension PAH Re-ascent from sea level to 2850m - Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease | Not applicable | Not yet recruiting | Silvia Ulrich Somaini | 20 | 2026-09-25 | 2026-09-04 |
| Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH Descent from 2850m to sea level - Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease | Not applicable | Not yet recruiting | Silvia Ulrich Somaini | 20 | 2026-09-25 | 2026-09-04 |
| Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH Re-Ascent sea level to 2850m - Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease | Not applicable | Not yet recruiting | Silvia Ulrich Somaini | 20 | 2026-09-25 | 2026-09-01 |
| Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAH Descent and re-ascent (2850m, sea level) - High Altitude Effects, High Altitude | Not applicable | Not yet recruiting | Silvia Ulrich Somaini | 20 | 2026-09-25 | 2026-09-03 |
| Sleep-Assessment in Patients Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH Descent to sea level - Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease | Not applicable | Not yet recruiting | Silvia Ulrich Somaini | 20 | 2026-09-25 | 2026-09-03 |
Showing 20 of 693. Sign in to see all of them.
Hypertension, Pulmonary (186) · Familial Primary Pulmonary Hypertension (32) · Heart Failure (18) · Lung Diseases, Interstitial (18) · Lung Diseases (16) · Cardiovascular Diseases (15) · Heart Defects, Congenital (15) · Hypertension (15) · Connective Tissue Diseases (13) · Hypoxia (12) · Motor Activity (12) · Scleroderma, Systemic (12) · Altitude Sickness (10) · Eisenmenger Complex (10)
Respiratory Tract Diseases (687) · Lung Diseases (677) · Hypertension, Pulmonary (507) · Cardiovascular Diseases (221) · Vascular Diseases (191) · Hypertension (179) · Pathological Conditions, Signs and Symptoms (56) · Heart Diseases (47) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (41) · Pathologic Processes (36) · Respiration Disorders (29) · Congenital Abnormalities (28) · Skin and Connective Tissue Diseases (27) · Cardiovascular Abnormalities (26) · Signs and Symptoms (24)
treprostinil (43) · Sildenafil Citrate (34) · Bosentan (29) · ambrisentan (24) · Iloprost (21) · macitentan (21) · ACE-011 (17) · Tadalafil (17) · selexipag (15) · riociguat (12) · zamicastat (11) · Epoprostenol (9) · sitaxsentan (9) · Blood Specimen Collection (7) · Imatinib Mesylate (6)
Actelion (59) · United Therapeutics (44) · Bayer (19) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (13) · Bial - Portela C S.A. (12) · Merck Sharp & Dohme LLC (12) · Novartis Pharmaceuticals (12) · Assistance Publique - Hôpitaux de Paris (10) · Pfizer (10) · University of Sao Paulo General Hospital (10) · GlaxoSmithKline (9) · Silvia Ulrich Somaini (9) · Vanderbilt University Medical Center (9) · Gilead Sciences (8) · Mayo Clinic (8)
United States (309) · Germany (119) · France (102) · United Kingdom (98) · Canada (85) · Spain (77) · Italy (76) · China (74) · Australia (67) · Belgium (65) · Poland (62) · Austria (54) · Netherlands (54) · Israel (50) · Brazil (48)
Rodrigo Hoyos (7) · Silvia Ulrich (7) · Steeve Provencher, MD, MSc (5) · Ashika Ahmed, MD (4) · Horst Olschewski, MD (4) · Jieyan Shen, PhD (4) · Rajan Saggar, MD (4) · Thenappan Thenappan, MD (4) · Alexander Khoruts, MD (3) · Aziz Laurent, MD (3)
PMID 16982941, PMID 18277824, PMID 20585012, PMID 21680644, PMID 22281797, PMID 23164592, PMID 23403476, PMID 23883378, PMID 26135803, PMID 26231884, PMID 27162632, PMID 27263466, PMID 27457511, PMID 28775050, PMID 29447737, PMID 29501590, PMID 30545968, PMID 31109190, PMID 31538282, PMID 31908813, PMID 33651671, PMID 34353714, PMID 34727317, PMID 35819570, PMID 36093166, PMID 38184507, PMID 38451426, PMID 39585521, PMID 40388087, PMID 40788460, PMID 41223909, PMID 41258625, PMID 42246435, PMID 10933371, PMID 12029189, PMID 1222951, PMID 12651053, PMID 15073478, PMID 15176691, PMID 15375007, PMID 15879413, PMID 16456139, PMID 17242010, PMID 17360728, PMID 17474643, PMID 18506008, PMID 18572079, PMID 1863023, PMID 19679693, PMID 19705340
2023 (12), 2017 (7), 2015 (6), 2018 (5), 2014 (4), 2016 (4), 2005 (2), 2008 (2), 2009 (2), 2019 (2), 2025 (2), 2004 (1), K23HL164901 (1), P01CA108671 (1), P01HL103455 (1)